Microsoft orders more Xbox layoffs, boss Phil Spencer tells staff "our platform, hardware, and game roadmap have never looked stronger" but the fourth big round of layoffs in 18 months is coming anyway
Microsoft has begun a new round of mass layoffs, impacting its gaming division despite Xbox boss Phil Spencer saying that the company's "platform, hardware, and game roadmap have never looked stronger."
Whispers of upcoming job cuts were reported by Bloomberg last week, which now writes that employees are being informed today of the plans. Candy Crush developer King is cutting around 200 jobs, affecting roughly 10% of its staff, according to the site's sources. The exact number of layoffs across other offices, such as in the US and the rest of Europe, isn't currently clear.
In a statement provided to GamesRadar+ on July 2, a Microsoft spokesperson says: "We continue to implement organizational and workforce changes that are necessary to position the company and teams for success in a dynamic marketplace."
While no specifics were provided confirming the number of Microsoft Gaming employees affected by the layoffs, it's stated that roughly 4% of Microsoft's total workforce has been impacted. As of last year, it was estimated that Microsoft employs roughly 228,000 people.
Bloomberg also shares an email that was sent to staff by Microsoft Gaming CEO Phil Spencer (posted in full by The Verge), who acknowledges that "these changes come at a time when we have more players, games, and gaming hours than ever before. Our platform, hardware, and game roadmap have never looked stronger."
However, he adds that "the success we're seeing currently is based on tough decisions we've made previously," and insists that "we must make choices now for continued success in future years, and a key part of that strategy is the discipline to prioritize the strongest opportunities.
"We will protect what is thriving and concentrate effort on areas with the greatest potential, while delivering on the expectations the company has for our business," Spencer continues. "This focused approach means we can deliver exceptional games and experiences for players for generations to come."
Spencer adds that "we would not be where we are today without the time, energy, and creativity of those whose roles are impacted," and says those affected are "encouraged to explore open positions across Microsoft Gaming, where their applications will be given priority review."
However, as Bloomberg points out, the situation feels particularly dire, given that this is the fourth round of layoffs since January 2024, when almost 2,000 people lost their jobs. After that, there was the closure of studios, including Arkane Austin and Tango Gameworks (the latter of which was later revived by Krafton), followed by the layoff of another 650 people a few months later.
The full situation still appears to be unfolding, with more details emerging gradually, as it's also been reported that Everwild, an action-adventure from Rare, has been canceled amidst the layoffs.
This article has been updated to include a statement from a Microsoft spokesperson.
Solve the daily Crossword

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
a few seconds ago
- Yahoo
Elis: Disclosure of trading in own shares occured from July 21 to July 24, 2025
Disclosure of trading in own shares occurred from July 21 to July 24, 2025 Saint-Cloud, July 28, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from July 21 to July 24, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer name Issuer code(LEI) Transaction date ISIN Code Daily total Volume (in number of shares) Daily weighted average price of shares acquired (in euros) Platform (MIC Code) ELIS SA 969500UX71LCE8MAY492 07/21/2025 FR0012435121 11,804 24.8578 XPAR ELIS SA 969500UX71LCE8MAY492 07/21/2025 FR0012435121 3,331 24.8084 DXE ELIS SA 969500UX71LCE8MAY492 07/22/2025 FR0012435121 9,205 24.7323 XPAR ELIS SA 969500UX71LCE8MAY492 07/22/2025 FR0012435121 4,798 24.6760 DXE ELIS SA 969500UX71LCE8MAY492 07/23/2025 FR0012435121 2,800 25.0457 XPAR ELIS SA 969500UX71LCE8MAY492 07/24/2025 FR0012435121 7,854 25.2264 XPAR ELIS SA 969500UX71LCE8MAY492 07/24/2025 FR0012435121 2,500 25.1880 DXE Total 42,292 24.9064 The purpose of the own shares purchase operations is (i) to cover maturing performance share plans and to allocate free shares to employees as part of the contribution to the Elis for All 2025 international employee shareholding plan, and (ii) to be cancelled in accordance with the 26th resolution of the Combined General Meeting of May 22, 2025. Contacts Nicolas BuronDirector of Investor Relations, Financing & TreasuryPhone: + 33 (0)1 75 49 98 30 - Charline LefaucheuxInvestor Relations Phone: + 33 (0)1 75 49 98 15 - Attachment Elis - Disclosure of trading in own shares occured from July 21 to July 24, 2025Sign in to access your portfolio
Yahoo
a few seconds ago
- Yahoo
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data